Hostname: page-component-89b8bd64d-rbxfs Total loading time: 0 Render date: 2026-05-08T12:20:40.535Z Has data issue: false hasContentIssue false

Erythrocyte phospholipid molecular species and fatty acids of Down syndrome children compared with non-affected siblings

Published online by Cambridge University Press:  24 November 2014

Allain A. Bueno
Affiliation:
Institute of Science and the Environment, University of Worcester, Henwick Grove, Worcester WR2 6AJ, UK
Annette Brand
Affiliation:
Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
Marita M. Neville
Affiliation:
Institute of Brain Chemistry and Human Nutrition, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK
Catherine Lehane
Affiliation:
Institute of Brain Chemistry and Human Nutrition, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK
Nina Brierley
Affiliation:
The Harley Street Clinic, 35 Weymouth Street, London W1G 8BJ, UK
Michael A. Crawford*
Affiliation:
Reproductive Physiology, Imperial College, London, Chelsea and Westminster Hospital Campus, 369 Fulham Road, London SW10 9NH, UK
*
* Corresponding author: Professor M. A. Crawford, fax +44 20 8846 7892, email michael.crawford@imperial.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

The majority of children with Down syndrome (DS) develop Alzheimer's disease (AD) at an early age. Although long-chain n-3 fatty acids (FA) are protective of neurodegeneration, little is known about the FA status in DS. In the present study, we aimed to investigate whether children with DS presented altered plasma and erythrocyte membrane phospholipids (PL) FA composition, when compared with their non-affected siblings. Venous blood samples were analysed for plasma and erythrocyte membrane FA composition by TLC followed by GC techniques. Lipid molecular species were determined by electrospray ionisation/tandem MS (ESI-MS/MS). FA analysis measured by standard GC showed an increased concentration of MUFA and a decreased concentration of plasmalogens in major PL fractions, but there were no differences in the concentrations of arachidonic acid or DHA. However, as identified by ESI-MS/MS, children with DS had increased levels of the following erythrocyte PL molecular species: 16 : 0–16 : 0, 16 : 0–18 : 1 and 16 : 0–18 : 2n-6, with reduced levels of 16 : 0–20 : 4n-6 species. Children with DS presented significantly higher levels of MUFA in both plasma and erythrocyte membrane, as well as higher levels of saturated and monounsaturated molecular species. Of interest was the almost double proportion of 16 : 0–18 : 2n-6 and nearly half the proportion of 16 : 0–20 : 4n-6 of choline phosphoacylglycerol species in children with DS compared with their non-affected siblings. These significant differences were only revealed by ESI-MS/MS and were not observed in the GC analysis. Further investigations are needed to explore molecular mechanisms and to test the association between the pathophysiology of DS and the risk of AD.

Information

Type
Full Papers
Copyright
Copyright © The Authors 2014 
Figure 0

Table 1 Age and sex of children with Down syndrome (DS) and their healthy siblings (HS) (Mean values with standard deviations, n 11 for HS and n 9 for DS)

Figure 1

Table 2 Fatty acid (FA) composition of erythrocyte ethanolamine (PtdEtn) and serine phosphoacylglycerols (PtdSer) in children with Down syndrome (DS) when compared with their healthy siblings (HS) (Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)

Figure 2

Table 3 Fatty acid (FA) composition of erythrocyte and plasma choline glycerophospholipids in children with Down syndrome (DS) when compared with their healthy siblings (HS) (Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)

Figure 3

Table 4 Fatty acid (FA) composition of erythrocyte sphingomyelin (CerPCho) and plasma cholesterol esters (CE) in children with Down syndrome (DS) when compared with their healthy siblings (HS) (Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)

Figure 4

Fig. 1 Activities of erythrocyte superoxide dismutase (SOD: Down syndrome (DS, ), n 8; healthy siblings (HS), n 7) and glutathione peroxidase (GPx: DS, n 9; control (), n 7) in children with DS when compared with their HS. Values are means, with their standard errors represented by vertical bars. * Mean value was significantly different from that of the HS group (P< 0·05). One unit of SOD is defined as the amount of enzyme needed to exhibit 50 % dismutation of the superoxide radical.

Figure 5

Fig. 2 Changes in choline phosphoacylglycerol (PC) molecular species in the erythrocyte membrane lipids of children with Down syndrome (DS, ) when compared with their healthy siblings (HS). (a) Section of a representative positive-ion electrospray ionisation-MS/MS spectrum of erythrocyte membrane PC from a healthy sibling . The spectrum shows [M+H]+ adducts only (see the ‘Subjects and methods’ section for details). (b) Palmitic acid (16 : 0)-containing PC species are expressed as the percentage of total erythrocyte membrane PC species. Values are means (HS, n 5; DS, n 5), with standard deviations represented by vertical bars. * Mean value was significantly different from that of the HS group (P< 0·05). m/z, mass:charge ratio; FA, fatty acid.

Supplementary material: PDF

Bueno Supplementary Material

Supplementary Material

Download Bueno Supplementary Material(PDF)
PDF 234.4 KB